Jounce Therapeutics Inc [JNCE] Rallies after Gilead Deal – What Next?
Jounce Therapeutics Inc [NASDAQ:JNCE] is a top performer this afternoon. After trading in a range all through August, the stock has gapped up and is in gains of close to 50%. This follows the company’s announcement that it was entering into an exclusive license agreement with Gilead Sciences for a novel immunotherapy program named JTX-1811. […]
Jounce Therapeutics Inc [JNCE] Rallies after Gilead Deal – What Next? Read More »